Oppenheimer Reiterates Outperform on Avadel Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintains a $22 price target.
June 12, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Avadel Pharmaceuticals and maintains a $22 price target.
The reiteration of the Outperform rating and maintenance of the $22 price target by Oppenheimer analyst Francois Brisebois indicates a positive outlook for Avadel Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100